KN5501 / Rui Therapeutics - LARVOL DELTA

...Center for Drug Evaluation (CDE) of the National Medical Products Administration has successively announced the implicit approval of clinical trials of...KN5501 cell injection of Shenzhen Enrui Kainuo Biological... [Google translation] (new.qq.com)

New trial • Immunology • Lupus • Rheumatoid Arthritis

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Changhai Hospital | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Immunology

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: YANRU WANG | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Immunology

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Changhai Hospital | Trial completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2024 ➔ May 2025

Enrollment open • Trial initiation date • Immunology • Inflammatory Arthritis • Rare Diseases • Rheumatoid Arthritis • Rheumatology

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Changzhou No.2 People's Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2026 ➔ Jul 2026 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Enrollment open • Trial completion date • Trial primary completion date • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Changhai Hospital | N=12 ➔ 36 | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Enrollment change • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Immunology • Inflammatory Arthritis • Rare Diseases • Rheumatoid Arthritis • Rheumatology

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Changzhou No.2 People's Hospital | Initiation date: Mar 2024 ➔ Aug 2024

Trial initiation date • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Changhai Hospital | Trial completion date: Aug 2026 ➔ Aug 2025 | Initiation date: Jul 2024 ➔ Aug 2023 | Trial primary completion date: Aug 2025 ➔ Aug 2024

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Changhai Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Renal Disease

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Changhai Hospital | Trial completion date: Aug 2025 ➔ Aug 2026 | Initiation date: Aug 2023 ➔ Jul 2024 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Changhai Hospital

New P1 trial • Renal Disease

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: YANRU WANG

New P1 trial • Immunology

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Changzhou No.2 People's Hospital

New P1 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Changhai Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Changhai Hospital

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Changhai Hospital

New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19